CFDE Data Portal | Search AMMECR1LP1

	Label	Description
	AMMECR1LP1 associations Collection (Entity type)	Associations for AMMECR1LP1_associations
	AMMECR1LP1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	AMMECR1LP1 Gene (Entity type)	ENSG00000233273 - AMMECR1 like pseudogene 1
	GSE100148 EZH2 inhibition 10 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE130437 palbociclib 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 7 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Pituitary 20-29 vs 40-49 Down Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Pituitary 20-29 vs 50-59 Down Gene Set (Entity type)	A Gene Set from GTEx
	GSE130396 neratinib 7 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE113375 DICER1 knockout 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

AMMECR1LP1 associations

Associations for AMMECR1LP1_associations

AMMECR1LP1 associations.tsv

A file from IDG as part of the Harmonizome project

AMMECR1LP1

ENSG00000233273 - AMMECR1 like pseudogene 1

GSE100148 EZH2 inhibition 10 v 5 human dn

A Gene Set from LINCS

GSE130437 palbociclib 2 v 1 human dn

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 7 v 5 human dn

A Gene Set from LINCS

GTEx Pituitary 20-29 vs 40-49 Down

A Gene Set from GTEx

GTEx Pituitary 20-29 vs 50-59 Down

A Gene Set from GTEx

GSE130396 neratinib 7 v 6 human up

A Gene Set from LINCS

GSE113375 DICER1 knockout 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.